Teva Pharmaceuticals has announced that it will no longer pursue the commercial development of laquinimod, a small-molecule aryl hydrocarbon receptor activator, in neurodegenerative diseases. The development and commercialization rights will revert back to Active Biotech, the company that originated the molecule. Read More